
    
      To assess the efficacy of autologous PBSCT versus FDA approved standard of care ( i.e.
      interferon, glatiramer acetate, mitoxantrone, natalizumab, fingolimod, or tecfidera) for
      inflammatory multiple sclerosis (MS) failing failing alternate approved therapy. The
      endpoints to be considered in this study are:

      2.1 Primary Endpoint:

      Disease progression, defined as a 1 point increase in the Expanded Disability Status Scale
      (EDSS) on consecutive evaluations at least 6 months apart and not due to a non-MS disease
      process. Patients will be followed for 5 years after randomization.
    
  